Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, drugmaker Eli Lilly (NYSE: LLY) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Lilly's business and see what CAPS investors are saying about the stock right now.

Lilly facts

Headquarters (founded) Indianapolis (1876)
Market Cap $46.7 billion
Industry Pharmaceuticals
Trailing-12-Month Revenue $24.3 billion
Management Chairman/CEO John Lechleiter
CFO Derica Rice
Return on Equity (average, past 3 years) 44.3%
Cash/Debt $6.9 billion / $7.0 billion
Dividend Yield 4.9%
Competitors GlaxoSmithKline
Pfizer
Sanofi

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 93% of the 1,389 members who have rated Lilly believe the stock will outperform the S&P 500 going forward.  

Late last month, one of those Fools, All-Star Staka, weighed the stock's pros and cons for our community:

Positive:
- Dividend, valuation
- Defensive
- Patens issues are well-known (priced in)

Negative:
- Litigation risks
- FDA risks

Of course, despite its four-star rating, Lilly may not be your top choice. If that's the case, we've compiled a special free report for investors called "Secure Your Future With 9 Rock-Solid Dividend Stocks," which uncovers several other juicy income opportunities. The report is 100% free, but it won't be around forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.